261 related articles for article (PubMed ID: 14731055)
21. The 'NICE' approach to technology assessment: an economics perspective.
Birch S; Gafni A
Health Care Manag Sci; 2004 Feb; 7(1):35-41. PubMed ID: 14977092
[TBL] [Abstract][Full Text] [Related]
22. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
Bryan S; Williams I; McIver S
Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
[TBL] [Abstract][Full Text] [Related]
23. 10 years of NICE: still growing and still controversial.
Littlejohns P; Garner S; Doyle N; Macbeth F; Barnett D; Longson C
Lancet Oncol; 2009 Apr; 10(4):417-24. PubMed ID: 19341973
[TBL] [Abstract][Full Text] [Related]
24. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
Taylor R
Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
[TBL] [Abstract][Full Text] [Related]
25. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making.
Dakin HA; Devlin NJ; Odeyemi IA
Health Policy; 2006 Aug; 77(3):352-67. PubMed ID: 16213624
[TBL] [Abstract][Full Text] [Related]
26. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
27. Has NICE been nice to cancer?
Summerhayes M; Catchpole P
Eur J Cancer; 2006 Nov; 42(17):2881-6. PubMed ID: 17070032
[TBL] [Abstract][Full Text] [Related]
28. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
Littlejohns P; Barnett D; Longson C;
Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
[TBL] [Abstract][Full Text] [Related]
29. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
Barbieri M; Hawkins N; Sculpher M
Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
[TBL] [Abstract][Full Text] [Related]
30. Clinical effectiveness and cost effectiveness of zanamivir (Relenza): translating the evidence into clinical practice, a National Institute for Clinical Excellence view.
Barnett D
Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1899-903. PubMed ID: 11779390
[TBL] [Abstract][Full Text] [Related]
31. The NICE cost-effectiveness threshold: what it is and what that means.
McCabe C; Claxton K; Culyer AJ
Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
[TBL] [Abstract][Full Text] [Related]
32. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
33. An evaluation of the impact of NICE guidance on GP prescribing.
Wathen B; Dean T
Br J Gen Pract; 2004 Feb; 54(499):103-7. PubMed ID: 14965388
[TBL] [Abstract][Full Text] [Related]
34. When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.
Longworth L; Youn J; Bojke L; Palmer S; Griffin S; Spackman E; Claxton K
Pharmacoeconomics; 2013 Feb; 31(2):137-49. PubMed ID: 23329429
[TBL] [Abstract][Full Text] [Related]
35. Report blames NICE for hastening decline of UK biotech.
Moran N
Nat Biotechnol; 2009 Mar; 27(3):215-7. PubMed ID: 19270658
[No Abstract] [Full Text] [Related]
36. Who bears the cost of NICE public health recommendations?
Hinde S; Wiyani A; Griffin S; Walker S
Br Med Bull; 2017 Dec; 124(1):113-120. PubMed ID: 29053776
[TBL] [Abstract][Full Text] [Related]
37. The NHS as an insurer.
Vaithianathan R; Lewis G
J Health Serv Res Policy; 2010 Jul; 15(3):171-3. PubMed ID: 20203080
[TBL] [Abstract][Full Text] [Related]
38. The ethics of attaching research conditions to access to new health technologies.
Holland S; Hope T
J Med Ethics; 2012 Jun; 38(6):366-71. PubMed ID: 22345547
[TBL] [Abstract][Full Text] [Related]
39. Implications of the appraisal function of the National Institute for Clinical Excellence (NICE).
Buxton M
Value Health; 2001; 4(3):212-6. PubMed ID: 11705183
[TBL] [Abstract][Full Text] [Related]
40. The NHS: assessing new technologies, NICE and value for money.
Stevens A; Chalkidou K; Littlejohns P
Clin Med (Lond); 2011 Jun; 11(3):247-50. PubMed ID: 21902077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
